ArticleNPJ precision oncology2026

Discovery of BEND4 as a novel single-gene prognostic marker and therapeutic target for adverse AML.

Archisman Banerjee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.